NCCN Organizing National Summit for Appropriate Use of REMS in Cancer Care
The National Comprehensive Cancer Network (NCCN) announces the NCCN REMS Oncology Summit scheduled for May 2010 to discuss recommendations for the appropriate application of Risk Evaluation and Mitigation Strategies (REMS) in cancer care.
January 12, 2010
FORT WASHINGTON, PA — Risk evaluation and mitigation strategies (REMS), which can be required by the FDA for drugs or biologics with significant toxicity and/or risks, are emerging as a priority topic for a variety of individuals. The goal of REMS to mitigate known or potential drug risks must be balanced with concerns that such programs may be overly complex and burdensome to physicians and other healthcare providers.
To provide direction from key stakeholders in the oncology arena on this important issue, the National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world’s leading cancer centers dedicated to improving the effectiveness and efficiency of care for patients with cancer, is taking a leadership role in the oncology community by planning the NCCN REMS Oncology Summit to discuss issues and recommendations regarding the appropriate application of REMS in oncology.
“Availability of and access to appropriate drugs are essential for patients with cancer. Therefore, the implications of policy decisions and processes regarding REMS must be carefully considered before the implementation of any new REMS policy paradigm,” says William T. McGivney, PhD, CEO of NCCN. “NCCN`s reputation in the cancer community properly positions us to take the lead in addressing REMS in such a way as to improve patient outcomes and ensure access to care.”
“Breadth of experience and access to a wide knowledge base are two characteristics that will ensure appropriate development and consideration of REMS within oncology that should be applicable to other clinical areas,” says Philip E. Johnson, MS, RPh, FASHP, Pharmacy Advocacy Director at H. Lee Moffitt Cancer Center Research Institute. “As the arbiter of high-quality cancer care based upon its world-leading institutions, clinicians, and pharmacists and its past record of developing the NCCN Clinical Practice Guidelines in Oncology™, widely accepted as the standard for clinical policy in oncology in the United States - NCCN is uniquely positioned to provide guidance in this process.”
During the REMS Summit, NCCN will present its recommendations regarding the development and implementation of REMS based on the expertise of pharmacists, pharmacy directors, medical oncologists/hematologists, patient advocates, policy makers, and representatives from specialty pharmacy, industry, government, and payors. The NCCN REMS Summit is scheduled for May 2010 in Washington D.C.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin Carbone Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital